Malignant lymphoma was associated with chromosome band 6q deletion pattern

08-18-2006

"Deletion of chromosome arm 6q is a frequent karyotypic alteration found in a variety of cancers and lymphoproliferative disorders, including leukemia and lymphomas. We characterized 6q deletions in 35 malignant lymphomas, using conventional and molecular cytogenetic approaches, to define the deletion pattern of 6q in different histological types," scientists in Italy reported.

"Conventional cytogenetics revealed a 6q deletion in 46% of lymphomas, including 2 cases that showed 6q deletion as the sole chromosome anomaly. Interphase FISH analysis demonstrated allelic loss of 6q regions in 33 out of 35 cases (94.2%); the deletions were discontinuous, involving nonadjacent molecular regions. Although 6q deletion is a common event in all types of lymphomas, specific deletion patterns seem to characterize different histological types, suggesting that different tumor suppressor genes play different roles in different types of lymphomas," explained M. Taborelli and colleagues, University of Insubria.

The researchers concluded, "Two specific 6q regions deleted in diffuse large B cell lymphomas but not in follicular lymphomas may be implicated in the clinical transformation."

Taborelli and colleagues published their study in Cancer Genetics and Cytogenetics (Chromosome band 6q deletion pattern in malignant lymphomas. Cancer Genet Cytogenet, 2006;165(2):106-113).

For more information, contact C. Capella, University of Insubria, Ospedale Circolo, Dept. Surgery Pathology Anatomy Patol, Viale Borri 57, I-21100 Varese, Italy.

This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2006, Clinical Oncology Week via NewsRx.com.



Related Diseases: Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma
Related Keywords: 6q, B Chronic Lymphocytic Leukemia (B-CLL), B-cells
Related Glossary Terms: NHL, Hodgkin Lymphoma
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
Spicy Pickle(TM) Teams With Leukemia & Lymphoma Society In 'Hike For Discovery' Fundraiser On July 18
Hana Biosciences' Marqibo Receives Orphan Designation From European Commission for the Treatment of Adult Acute Lymphoblastic Leukemia
Cancer drug shows promise against graft vs. host disease
Best and brightest leukemia researchers receive $1-million from Cole Foundation
Microenvironment a main driver of aggressive multi-lineage leukemia disease type
Acute Myeloid Leukemia (AML)
Genome Sequencer FLX System plus NimbleGen Sequence Capture Arrays Help Unravel the Cryptic Genetic Changes in Hematological Malignancies
Early findings show promise as AS1411 AML study proceeds to higher-dose stage
Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Radiation Therapy for Prostate Cancer Increases Incidence of AML
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma
Patients with Lymphoma and CLL Are at Increased Risk of Lung Cancer
Best and brightest leukemia researchers receive $1-million from Cole Foundation
Microenvironment a main driver of aggressive multi-lineage leukemia disease type
New lymphoma therapies targets diverse and difficult cancer
Chronic Myeloid Leukemia (CML)
Activation of LYN kinase is associated with imatinib-resistance in CML patients
CHEMGENEX'S OMACETAXINE DEMONSTRATES ACTIVITY IN CML PATIENTS WHO HAVE FAILED THERAPY WITH MULTIPLE TYROSINE KINASE INHIBITORS
Best and brightest leukemia researchers receive $1-million from Cole Foundation
Microenvironment a main driver of aggressive multi-lineage leukemia disease type
Combination of two novel anti-cancer agents may help fight CML resistant to current therapy
Hodgkin Lymphoma
OSI Pharmaceuticals Begins Clinical Development Program for OSI-027 in Patients with Advanced Solid Tumors or Lymphoma
Spicy Pickle(TM) Teams With Leukemia & Lymphoma Society In 'Hike For Discovery' Fundraiser On July 18
Hana Biosciences' Marqibo Receives Orphan Designation From European Commission for the Treatment of Adult Acute Lymphoblastic Leukemia
Cancer drug shows promise against graft vs. host disease
Hodgkin's lymphoma survivors show higher risk of second cancers
Multiple Myeloma
Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
Does a 10-year 10% Continuous Complete Remission Rate for Myeloma Patients Suggest Cure?
Thalidomide Plus Dexamethasone: Improved Primary Myeloma Therapy
Bone Pain Can Be A Sign Of Myeloma - Patients And Doctors Join Forces To Raise Awareness Of Early Myeloma Diagnosis
Lenalidomide raises clot risk in multiple myeloma patients
Myelodysplastic Syndrome (MDS)
Xanthus Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine (VNP40101M) in Combination with Cytarabine
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
Scoring system identifies MDS patients who have low-risk disease but a poor prognosis
Seattle Genetics Initiates Phase IIb Clinical Trial of SGN-33 in Combination with Chemotherapy for Acute Myeloid Leukemia
Non-Hodgkin Lymphoma (NHL)
CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
Ofatumumab Promising in Refractory Follicular Lymphoma
OSI Pharmaceuticals Begins Clinical Development Program for OSI-027 in Patients with Advanced Solid Tumors or Lymphoma
Spicy Pickle(TM) Teams With Leukemia & Lymphoma Society In 'Hike For Discovery' Fundraiser On July 18
Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma
Testicular Cancer
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer
Drug avoids radiation for early testicular cancer
Polymorphism Reduces Benefit of Bleomycin in Testicular Cancer
Increased Life Expectancy Seen For Patients With Advanced Colorectal, Ovarian and Testicular Cancer